MRRSE.Com Announces addition of new report"ovarian cancer"to its database

1. Worldwide Ovarian Cancer Therapeutics in Asia-
Pacific Markets to 2020
Albany, New York, April 29, 2015 : Market Research Reports Search Engine (MRRSE), a leading
portal offering business intelligence reports, has announced the addition of a new report on the
ovarian cancer therapeutics market with a focus on Asia Pacific. The report is titled “Ovarian
Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain
Dominance Despite New Launches”.
Currently, the therapies developmental pipeline is abuzz with activity but the efficacy of these
drugs is still below the expected standard. Progress still needs to be made in improving the overall
survival rates of patients suffering from OC. Drugs candidates that show the most potential
currently are trebananib and olaparib. These two drugs will likely obtain the regulatory nod during
the forecast period of this report. Analysts forecast that it will be a while before these drugs are
able to achieve a significant degree of market penetration. Moreover, the premium prices of these
drugs will further limit their acceptance.
Browse Full Report with TOC : http://www.mrrse.com/ovarian-cancer-therapeutics
Thus, new drug approvals cannot be listed as a driver for the Asia Pacific ovarian cancer
market. Growth will effectively occur as a result of inflationary forces and the general increase in
the pervasiveness of ovarian cancer. The report forecasts that the revenues in the APAC OC
market will rise at a meager 5.1% CAGR through the forecast period, touching US$417.6 million by
2020.
The report estimates market revenues and size for the period 2013 to 2020 for key markets in the
Asia Pacific region, namely, China, India, Japan and Australia. The report begins with the coverage
of the disease epidemiology, treatment patterns and algorithms, as well as a detailed analysis of
the clinical trials at various stages. A pipeline analysis of the ovarian cancer therapeutics market is
yet another vital component of the report.
Findings of the report state that platinum-based chemotherapy—more specifically paclitaxel and
carboplatin regimens—is the customary treatment, in the case of ovarian cancer that is sensitive to
platinum. This line of treatment is offered in the case of both first-time as well as recurrent ovarian
cancer. The initial treatment of the disease has proven to be effective, with the vast majority of
patients reporting remission of their disease. However, the analysis also states that nearly all of
these cases experience a relapse – ultimately leading to mortality or the emergence of platinum-
resistant ovarian cancer (the prognosis for which is currently poor).
The report identifies a wide gap in the current ovarian cancer market for maintenance therapies. A
pressing need is also felt for treatment options that are more effective, especially in patients with
platinum-resistant OC.

2. 1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Pathophysiology
2.1.1 Ovarian Cancer – A Group of Distinct Diseases
2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways
2.2 Symptoms and Diagnosis
2.3 Risk Factors
2.3.1 Age
2.3.2 Inherited Genetic Mutations
2.3.3 Greater Number of Lifetime Ovulations
2.3.4 Weight
2.3.5 Previous Medical Conditions
2.4 Treatment Algorithm
2.4.1 Surgery
2.4.2 First-Line Chemotherapy
2.4.3 Maintenance Therapy
2.5 Recurrent Disease
Send An Enquiry : http://www.mrrse.com/enquiry/112
3 Marketed Products
3.1 Carboplatin
3.2 Paclitaxel
3.3 Gemcitabine
3.4 Topotecan
3.5 Pegylated Liposomal Doxorubicin
3.6 Yondelis
3.7 Avastin
4 Product Pipeline
4.1 Overview of Pipeline by Phase and Route of Administration
4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target
4.2.1 Molecular Targets in the Developmental Pipeline
4.3 Clinical Trials
4.3.1 Clinical Trial Duration
4.3.2 Clinical Trial Size
4.3.3 Failure Rate
4.3.4 Discussion
4.4 Late-Stage Drugs in Developmental Pipeline
4.4.1 Niraparib
4.4.2 Olaparib

3. 4.4.3 Vargatef
4.4.4 Trebananib
4.4.5 Farletuzumab
4.4.6 Karenitecin
4.5 Discussion
5 Market Forecasts
5.1 Asia-Pacific
5.1.1 Overview
5.1.2 Treatment Use Patterns and Revenues in Asia-Pacific Markets
5.2 India
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Forecast
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Forecast
5.4 Japan
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Australia
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Forecast
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers
6 Deals
6.1 Licensing Deals
6.1.1 Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338
6.1.2 PharmaMar Enters into Licensing Agreement with Janssen for Yondelis
6.1.3 Hana Enters into Licensing Agreement with Tekmira
6.1.4 AstraZeneca Enters into Licensing Agreement with Merck for MK-1775
6.1.5 Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug
6.1.6 Oasmia Enters into Licensing Agreement with Medison for Paclical
6.1.7 Orion Enters into Agreement with Oasmia
6.1.8 Ohio University Enters into Licensing Agreement with Phosplatin
6.1.9 Genta Enters into Licensing Agreement with Daiichi Sankyo
6.1.10 Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research
6.1.11 NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300
6.2 Co-development Deals

4. 6.2.1 Bristol-Myers Squibb Enters into Co-development Agreement with Ono Pharma
6.2.2 Merck Enters into Co-development Agreement with Endocyte for Cancer Drug
6.2.3 Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate
Centre
6.2.4 Almac Discovery Enters into an Agreement with Queen’s University Belfast for Drug Discovery
7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Pre-Registration
7.2 Market Forecasts to 2020
7.2.1 Asia-Pacific
7.2.2 India
7.2.3 China
7.2.4 Japan
7.2.5 Australia
7.3 Abbreviations
7.4 Bibliography
7.5 Research Methodology
7.5.1 Coverage
7.5.2 Secondary Research
7.5.3 Primary Research
7.5.4 Therapeutic Landscape
7.5.5 Geographical Landscape
7.5.6 Pipeline Analysis
7.6 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer
About Us
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market
intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of
research experts and advisors trained to offer objective advice. Our sophisticated search algorithm
returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to
top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead

5. of the next new trend in market research, be it competitive intelligence, product or service trends or
strategic consulting.
Contact Us:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/
Blog: http://mrrse.blogspot.com/

6. of the next new trend in market research, be it competitive intelligence, product or service trends or
strategic consulting.
Contact Us:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/
Blog: http://mrrse.blogspot.com/